Application of solute carrier protein SLC43A2 as marker in preparation of product for diagnosis and/or prognosis evaluation of esophageal cancer

The embodiment of the invention discloses application of solute carrier protein SLC43A2 as a marker in preparation of a product for diagnosis and/or prognosis evaluation of esophageal cancer. The invention assists diagnosis and prognosis evaluation of esophageal squamous cell carcinoma patients through expression of a biomolecular index SLC43A2, and provides a prediction method for solving the current situation of lack of diagnosis and prognosis evaluation means of esophageal carcinoma patients. Meanwhile, a new target spot is provided for molecular targeted therapy of a patient with esophageal squamous carcinoma, and a new thought is provided for formulating a molecular targeted therapy strategy based on tumor metabolism by combining the important function of the molecule in methionine metabolism; in addition, the NF [kappa] B pathway inhibitor Bay 11-7082 is accidentally found to be capable of inhibiting expression and functions of the SLC43A2 in a targeting manner, and an optional medicine is provided for